← Leaderboards
Jonathan D Cooper
King'S College London
$5,725,988
Attributed
$9,497,250
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,497,250 · 9
By mechanism
RM1$4,754,001 · 1
R01$2,542,210 · 2
R21$1,272,088 · 3
R56$502,428 · 1
R43$411,523 · 1
R13$15,000 · 1
Top collaborators
- Patricia I Dickson3 shared
- Sean Ekins3 shared
- Fuhai Li3 shared
- Marco Sardiello3 shared
Others in their field
Top investigators on “Enzymes”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Randall J Bateman · Washington University$83,824,814
- Stuart L Schreiber · Harvard University (Medical School)$49,424,554
- Jay D Keasling · University Of California-Berkeley$47,558,861
- David Heimbrook · Leidos Biomedical Research, Inc.$47,513,682
- Susan Abushakra · Alzheon, Inc.$47,265,244
Research focus
EnzymesBrainNerve DegenerationNeuronal Ceroid-LipofuscinosisNeurodegenerative DisordersDisease ProgressionAffectChildhoodSpielmeyer-Vogt DiseaseRouteChildMediatingGene TherapySpinal CordThioesterase Ppt1 Gene ProductMouse ModelDisease PhenotypePathologyInfancyCln1 GeneOrganPhenotypeEffective TherapyResponse
Grant awards (19)
Systems-Level Approach to Neuronopathic Lysosomal Storage Disorders$1,590,711
RM1 · FY2025 · NS
Cellular Mechanisms of Enteric Nervous System Damage in CLN2 Disease$643,377
R01 · FY2025 · NS · contact PI
Characterizing and testing the efficacy of AAV-mediated gene therapy in a sheep model of CLN1 disease.$336,000
R01 · FY2025 · NS · contact PI
Systems-Level Approach to Neuronopathic Lysosomal Storage Disorders$1,558,704
RM1 · FY2024 · NS
Characterizing and testing the efficacy of AAV-mediated gene therapy in a sheep model of CLN1 disease.$490,319
R01 · FY2024 · NS · contact PI
Systems-Level Approach to Neuronopathic Lysosomal Storage Disorders$1,604,586
RM1 · FY2023 · NS
Characterizing and testing the efficacy of AAV-mediated gene therapy in a sheep model of CLN1 disease.$521,882
R01 · FY2023 · NS · contact PI
Defining and treating peripheral nervous system dysfunction in Cln1 disease$236,250
R21 · FY2023 · NS · contact PI
Characterizing and testing the efficacy of AAV-mediated gene therapy in a sheep model of CLN1 disease.$550,632
R01 · FY2022 · NS · contact PI
Defining and treating peripheral nervous system dysfunction in Cln1 disease$196,875
R21 · FY2022 · NS · contact PI
Characterizing and testing the efficacy of AAV-mediated gene therapy in a novel CRISPR/Cas9 generated sheep model of Cln1 disease.$502,428
R56 · FY2021 · NS · contact PI
Defining and treating enteric nervous system damage in Cln1 disease$454,213
R21 · FY2020 · NS · contact PI
NCL2020, The 17th International Congress on the Neuronal Ceroid Lipofuscinoses (NCLs) or Batten Disease$15,000
R13 · FY2020 · NS · contact PI
Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses$127,300
R43 · FY2019 · NS
Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses$54,663
R43 · FY2019 · NS
Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses$229,560
R43 · FY2018 · NS
Comparative Morphology of Neuronal Ceroid Lipofuscinosis$128,250
R21 · FY2004 · NS
Comparative Morphology of Neuronal Ceroid Lipofuscinosis$128,250
R21 · FY2003 · NS
Comparative Morphology of Neuronal Ceroid Lipofuscinosis$128,250
R21 · FY2002 · NS